Journal of the American Academy of Dermatology
Volume 54, Issue 1 , Pages 82-85 , January 2006

Use of high-dose acyclovir in pityriasis rosea

,Accepted 27 June 2005.

References 

  1. Drago F, Ranieri E, Malaguti F, Losi E, Rebora A. Human herpesvirus 7 and pityriasis rosea. Lancet. 1997;349:1367–1368
  2. Watanabe T, Kawamura T, Jacob SE, Aquilino EA, Orenstein JM, Black JB, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol. 2002;119:793–797
  3. Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, et al. Additional evidence that pityriasis rosea is associated with reactivation of HHV-6 and HHV-7. J Invest Dermatol. 2005;124:1234–1240
  4. Burns WH, Sandford GR. Susceptibility of human herpesvirus-6 to antivirals in vitro. J Infect Dis. 1990;162:634–637
  5. Yoshida M, Yamada M, Tsukazaki T, Chatterjee S, Lakeman FD, Nii S, et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res. 1998;40:73–84
  6. De Araujo T, Berman B, Weinstein A. Human herpesviruses 6 and 7. Dermatol Clin. 2002;20:301–306
  7. Drago F, Rebora A. The new herpesviruses: emerging pathogens of dermatological interest. Arch Dermatol. 1999;135:71–75
  8. Castanedo-Cazares JP, Lepe V, Moncada B. Should we still use phototherapy for Pityriasis rosea?. Photodermatol Photoimmunol Photomed. 2003;19:160–161
  9. Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2000;42:241–244

 Funding sources: None.Conflicts of interest: None identified.

PII: S0190-9622(05)02113-4

doi: 10.1016/j.jaad.2005.06.042

Journal of the American Academy of Dermatology
Volume 54, Issue 1 , Pages 82-85 , January 2006

Article Tools